Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Feb 9

PMID 33557355

Citations 4

Authors

Saad Emhmed Ali

Mindie H Nguyen

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) continues to rise and has become the most common cause of chronic liver disease among all ages and ethnicities. Metabolic disorders, such as obesity and insulin resistance, are closely associated with sarcopenia and NAFLD. Sarcopenic obesity is a clinical disorder characterized by the simultaneous loss of skeletal muscle and gain of adipose tissue. It is associated with worse outcomes in individuals with NAFLD. It is projected that NAFLD and sarcopenia will rise as the prevalence of obesity continues to increase at an unparallel rate. Recently, sarcopenia and sarcopenic obesity have gained considerable interest, but we still lack a well-defined definition and a management approach. Therefore, it is imperative to continue shining the light on this topic and better understand the underlying mechanism as well as treatment options. In this review article, we aimed to address the pathophysiology, impact, and outcomes of sarcopenic obesity on NAFLD.

Citing Articles

Sarcopenia in MASLD-Eat to Beat Steatosis, Move to Prove Strength.

Crisan D, Avram L, Morariu-Barb A, Grapa C, Hiriscau I, Craciun R Nutrients. 2025; 17(1.

PMID: 39796612 PMC: 11722590. DOI: 10.3390/nu17010178.

Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.

Park H, Lee S, Lee J Abdom Radiol (NY). 2024; 49(9):3036-3044.

PMID: 38587630 DOI: 10.1007/s00261-024-04285-w.

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis.

Gallo P, Flagiello V, Falcomata A, Di Pasquale G, DAvanzo G, Terracciani F J Clin Transl Hepatol. 2024; 12(3):278-286.

PMID: 38426198 PMC: 10899871. DOI: 10.14218/JCTH.2023.00207.

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.

Ng C, Huang D, Nguyen M Clin Mol Hepatol. 2022; 28(4):790-801.

PMID: 35545437 PMC: 9597238. DOI: 10.3350/cmh.2022.0070.

Prevalence of Non-alcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain.

Mohamed A, Isa H, Ali M, Dadi A, Kadhim Z Oman Med J. 2022; 37(2):e350.

PMID: 35356372 PMC: 8941014. DOI: 10.5001/omj.2022.53.

References

Yeap B . Are declining testosterone levels a major risk factor for ill-health in aging men?. Int J Impot Res. 2008; 21(1):24-36. DOI: 10.1038/ijir.2008.60. View

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X . Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2006; 92(3):895-901. PMC: 2714766. DOI: 10.1210/jc.2006-1393. View

Koo B, Kim D, Joo S, Kim J, Chang M, Kim B . Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2016; 66(1):123-131. DOI: 10.1016/j.jhep.2016.08.019. View

Gusmao-Sena M, Curvello-Silva K, Barreto-Medeiros J, Da-Cunha-Daltro C . Association between sarcopenic obesity and cardiovascular risk: where are we?. Nutr Hosp. 2016; 33(5):592. DOI: 10.20960/nh.592. View

Kim Y, Lee Y, Chung Y, Lee D, Joo N, Hong D . Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci. 2012; 67(10):1107-13. DOI: 10.1093/gerona/gls071. View

Hong H, Hwang S, Choi H, Yoo H, Seo J, Kim S . Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2013; 59(5):1772-8. DOI: 10.1002/hep.26716. View

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

Sharma D, Hawkins M, Abramowitz M . Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States. Clin J Am Soc Nephrol. 2014; 9(12):2079-88. PMC: 4255396. DOI: 10.2215/CJN.02140214. View

10.

Conley K, Esselman P, Jubrias S, Cress M, Inglin B, Mogadam C . Ageing, muscle properties and maximal O(2) uptake rate in humans. J Physiol. 2000; 526 Pt 1:211-7. PMC: 2270003. DOI: 10.1111/j.1469-7793.2000.00211.x. View

11.

Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S . Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011; 54(6):1491-501. DOI: 10.1007/s00125-011-2079-7. View

12.

Bonala S, McFarlane C, Ang J, Lim R, Lee M, Chua H . Pid1 induces insulin resistance in both human and mouse skeletal muscle during obesity. Mol Endocrinol. 2013; 27(9):1518-35. PMC: 5415229. DOI: 10.1210/me.2013-1048. View

13.

Kim T, Yang S, Yoo H, Lim K, Kang H, Song W . Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond). 2009; 33(8):885-92. DOI: 10.1038/ijo.2009.130. View

14.

Kim T, Choi K . The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J Cell Biochem. 2014; 116(7):1171-8. DOI: 10.1002/jcb.25077. View

15.

Gupta A, Das A, Majumder K, Arora N, Mayo H, Singh P . Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2017; 41(9):874-881. PMC: 5700876. DOI: 10.1097/COC.0000000000000388. View

16.

Schrager M, Metter E, Simonsick E, Ble A, Bandinelli S, Lauretani F . Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol (1985). 2006; 102(3):919-25. PMC: 2645665. DOI: 10.1152/japplphysiol.00627.2006. View

17.

Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff S . ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2016; 36(1):49-64. DOI: 10.1016/j.clnu.2016.09.004. View

18.

Choi K . Sarcopenia and sarcopenic obesity. Korean J Intern Med. 2016; 31(6):1054-1060. PMC: 5094937. DOI: 10.3904/kjim.2016.193. View

19.

Zou B, Yeo Y, Nguyen V, Cheung R, Ingelsson E, Nguyen M . Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020; 288(1):139-151. DOI: 10.1111/joim.13069. View

20.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View